Dr. Florence Porterfield, MD
Obesity Medicine Clinical Advisor
Massachusetts General Hospital
University of Pennsylvania School of MedicineAnytime. Anywhere.
Own your GLP-1 journey
with personalized coaching
The first AI-powered wellness coach designed for people using GLP-1s, by clinicians and GLP-1 users
95%
Why choose Alnu Health?
GLP-1s are transforming lives - but not without challenges. Alnu Health is built to support you, never prescribe.
70%
Of users report side effects, most common gastrointestinal, including nausea, vomiting, and diarrhea [1].
50-68%
Stop GLP-1 treatment within a year before achieving meaningful health outcomes [2-4].
2/3
of lost weight can be regained within 1 year when GLP-1 treatment is discontinued [5-7].
15-25%
Of total weight reduction can be lean muscle mass loss in absence of strength training program [8].
Get started today
Alnu Health is your companion helping monitor your journey, get personalized advice, and receive answers to your questions. You can easily track and get insights on your medication, side effects, nutrition and activity within seconds.
Alnu Health features
Track what matters — from meals and movement to side effects and progress. Alnu gives you smart tools, and personalized insights, at every step of your journey.
Track your journey
Monitor your weight, GLP-1 dose, side effects in one place - see trends and stay in control of your progress.
Monitor your side effects
Log and track common GLP-1 side effects like nausea, constipation, or fatigue. Get personalized tips to reduce discomfort and improve adherence.
Personalize nutrition coaching and tracking
Get personalized caloric and macro goals - snap a photo or describe your meal for real time AI powered analysis on nutrition, all tailored to your GLP-1 journey.
Track and optimize daily activity
Stay active, your way. Generate and track activities that support your GLP-1 progress — from stretches to strength training. Seamlessly integrate with your wearables to keep you on track.
Get context aware responses
Your Alnu Health Coach connects the dots across your journey - offering daily guidance based on how you`re feeling, eating, and progressing. Your coach helps to prepare you for your check-ins.
Created in partnership with doctors from
Alnu Health is backed by leading medical professionals specializing in endocrinology, weight management, and nutrition science, ensuring our platform delivers personalized research backed guidance along your GLP-1 journey.
How does it work?
It is a journey. We're here for you every step of the way
Step 1
Sign up
Download the app to begin owning your GLP-1 journey.
Step 2
Log & share how you're feeling
Log your injections, side effects, meals, or progress for real time support
Step 3
Get instant, actionable coaching
Receive real-time support that meets you where you're at in your journey. Anytime, anywhere.
Get started with the Alnu Health App
Testimonials
Hear from Alnu Health members who have transformed their GLP-1 experience
Alnu Health's personalized approach has been a game-changer. The AI meal suggestions actually fit my preferences, and my coach understood exactly what I was going through with my GLP-1 medication.
I was using multiple different apps to track my meals, medication, weight, and side effects. Alnu Health brought everything together in one place and added personalized recommendations that actually work with my lifestyle.
I was struggling with hair loss, and the Alnu Coach helped me understand why it was happening and that I wasn't alone. Their guidance made all the difference in managing this side effect.
I've been recommending Alnu Health to my GLP-1 patients as it provides the nutritional guidance they need between appointments. The personalized approach helps them stay on track with their treatment.
Alnu Health fills a critical gap in GLP-1 treatment by providing evidence-based nutrition and lifestyle support. My patients who use it report fewer side effects and better adherence to their medication."
"With only 15 minutes per appointment, I never have enough time to discuss lifestyle adjustments with my GLP-1 patients. Alnu Health fills this coaching gap and leads to more efficient check-ins where we can focus on medication adjustments."
Guided by Experts. Built for You.
Alnu Health’s clinical advisors bring decades of experience in weight management, nutrition, and behavioral health. Together, they help us turn complex science into simple, supportive guidance so you can own your GLP-1 journey with confidence and care.
Massachusetts General Hospital University of Pennsylvania School of Medicine
Dr. Bryn Faldhee, MD
Obesity Medicine & Gastroenterology Clinical Advisor
Weill Cornell
Harvard Medical School
Julia Lloyd, RD, MPH
Founding Dietitian and Clinical Advisor
Massachusetts General Hospital
University of Kentucky
Ready to own your GLP-1 journey?
Join the Alnu Health community to complement your GLP-1 journey with personalized support.
References
1. Rodriguez PJ, et al.
Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Netw Open. 2025 Jan 2;8(1):e2457349. doi: 10.1001/jamanetworkopen.2024.57349
2. D. Do, T. Lee, S.K. Peasah, C.B. Good, A. Inneh, U. Patel,
GLP-1 receptor agonist discontinuation among patients with obesity and/or type 2 diabetes, JAMA Netw Open 7 (5) (2024) e2413172.
3. P. Gleason, B. Urick, L. Marshall, Y. Qiu, S. Leslie, N. Friedlander, M. Chodroff, D. Lessen,
Real-world analysis of glucagon-like peptide-1 (GLP-1) agonist obesity treatment year-two clinical and cost outcomes, Prime Therapeutics, 2024.
4. P.P. Gleason, B.Y. Urick, L.Z. Marshall, N. Friedlander, Y. Qiu, R.S. Leslie,
Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes, J Manag Care Spec Pharm 30 (8) (2024) 860–867.
5. Aronne, N. Sattar, D.B. Horn, H.E. Bays, S. Wharton, W.Y. Lin, N.N. Ahmad, S. Zhang, R. Liao, M.C. Bunck, et al.,
Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial, JAMA 331 (1) (2024) 38–48.
6. D. Rubino, N. Abrahamsson, M. Davies, D. Hesse, F.L. Greenway, C. Jensen, et al.,
Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial, JAMA 325 (14) (2021) 1414–1425.
7. J.P.H. Wilding, R.L. Batterham, M. Davies, L.F. Van Gaal, K. Kandler, K. Konakli, I. Lingvay, B.M. McGowan, T.K. Oral, J. Rosenstock, et al.,
Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension, Diabetes Obes Metab 24 (8) (2022) 1553–1564.
8. Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, Bonnet J, Butsch WS, Christensen S, Gianos E, Gulati M, Gupta A, Horn D, Kane RM, Saluja J, Sannidhi D, Stanford FC, Callahan EA.
Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025 May 30. doi: 10.1002/oby.24336. Epub ahead of print. PMID: 40445127.